Advertisement

Current Addiction Reports

, Volume 5, Issue 4, pp 454–463 | Cite as

The Deepening Opioid Crisis in North America: Historical Context and Current Solutions

  • Joseph H. DonroeEmail author
  • M. Eugenia Socias
  • Brandon D. L. Marshall
Opioids (D Fiellin and J Donroe, Section Editors)
  • 222 Downloads
Part of the following topical collections:
  1. Topical Collection on Opioids

Abstract

Purpose of Review

The purpose of this review is to (1) detail the historical context behind the rise of opioid use disorder (OUD) and opioid-related harms in the United States (US) and Canada, (2) describe the epidemiology of OUD in these two countries, and (3) discuss current strategies being employed to address this public health emergency in North America.

Recent Findings

Opioid-related overdose has become a leading cause of unintentional injury related death in North America. Deaths have risen in parallel with opioid prescribing and the rising prevalence of unintentional exposure to highly potent synthetic opioids. At the same time, rates of injection drug use-related infections such as hepatitis C and endocarditis have also increased.

Summary

Both Canada and the US have implemented policy changes and interventions at the national and local levels in an attempt to stem rising opioid attributable morbidity and mortality. In many settings, the collective goal has been to increase access to treatment of OUD, expand harm reduction interventions (including improved access to naloxone), and develop and disseminate guidelines on the safe prescribing of opioids for non-cancer pain and the management of OUD.

Keywords

Opioid Addiction Overdose North America Fentanyl Heroin 

Notes

Acknowledgements

M. Eugenia Socias is supported by a Michael Smith Foundation for Health Research (MSFHR)/St Paul’s Foundation Scholar Award.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance

  1. 1.
    Ahmad FB, Rossen LM, Spencer MR, Warner M, Sutton P. Provisional drug overdose death counts: National Center for Health Statistics; 2018 [cited February 18, 2018]. Available from: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm.
  2. 2.
    Special Advisory Committee on the Epidemic of Opioid Overdoses. National report: apparent opioid-related deaths in Canada (January 2016 to September 2017) Web-based report. Ottawa: Public Health Agency of Canada; 2018. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/national-report-apparent-opioid-related-deaths-released-march-2018.html. Accessed 29 March 2018Google Scholar
  3. 3.
    Centers for Disease Control and Prevention. Annual Surviellance Report of Drug-Related Risks and Outcomes- United States, 2017. Surveillance Special Report 1: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2017. Available from: https://www.cdc.gov/drugoverdose/pdf/pubs/2017cdc-drug-surveillance-report.pdf. Accessed 12 March 2018
  4. 4.
    Berterame S, Erthal J, Thomas J, Fellner S, Vosse B, Clare P, et al. Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study. Lancet. 2016;387(10028):1644–56.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Fischer B, Argento E. Prescription opioid related misuse, harms, diversion and interventions in Canada: a review. Pain Physician. 2012;15(3 Suppl):ES191–203.PubMedPubMedCentralGoogle Scholar
  6. 6.
    • Murphy Y, Goldner EM, Fischer B. Prescription opioid use, harms and interventions in Canada: a review update of new developments and findings since 2010. Pain Physician. 2015;18(4):E605–14 This narrative review synthesized key information on prescription opioid dispensing, non medical use, related-harms, interventions and impacts in Canada between 2010 and 2015. PubMedPubMedCentralGoogle Scholar
  7. 7.
    Fischer B, Keates A, Buehringer G, Reimer J, Rehm J. Non-medical use of prescription opioids and prescription opioid-related harms: why so markedly higher in North America compared to the rest of the world? Addiction. 2014;109(2):177–81.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    • Humphreys K. Avoiding globalisation of the prescription opioid epidemic. Lancet. 2017;390(10093):437–9 This offers a concise review of the role of the pharmaceutical industry on the rising rates of opioid addiction and overdose. PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Busse JW, Craigie S, Juurlink DN, Buckley DN, Wang L, Couban RJ, et al. Guideline for opioid therapy and chronic noncancer pain. CMAJ. 2017;189(18):E659–E66.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Quinones S. Dreamland: the true tale of America’s opiate epidemic. New York: Bloomsbury Press; 2015. 374 pGoogle Scholar
  11. 11.
    Hadland SE, Krieger MS, Marshall BDL. Industry payments to physicians for opioid products, 2013-2015. Am J Public Health. 2017;107(9):1493–5.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    United States of America v. The Purdue Frederick Company, Inc., et al. Hearing before the US District Court for the Western District of Virginia. 2007.Google Scholar
  13. 13.
    OxyContin and OxyNEO national settement agreement 2018. Available from: https://www.wagners.co/current-class-actions/oxycontin/. Accessed 28 May 2018
  14. 14.
    Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL, Clark TW, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36(1):559–74.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain. 1986;25(2):171–86.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Weisberg DF, Becker WC, Fiellin DA, Stannard C. Prescription opioid misuse in the United States and the United Kingdom: cautionary lessons. Int J Drug Policy. 2014;25(6):1124–30.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    A consensus statement from the American Academy of Pain Medicine and the American Pain Society. The use of opioids for the treatment of chronic pain. Clin J Pain. 1997;13(1):6–8.Google Scholar
  18. 18.
    Ornstein C, Weber T. American pain Foundation shuts down as senators launch investigation of prescription narcotics: ProPublica; 2012. Available from: https://www.propublica.org/article/senate-panel-investigates-drug-company-ties-to-pain-groups.
  19. 19.
    King NB, Fraser V, Boikos C, Richardson R, Harper S. Determinants of increased opioid-related mortality in the United States and Canada, 1990–2013: a systematic review. Am J Public Health. 2014;104(8):e32–42.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Guy GP Jr, Zhang K, Bohm MK, Losby J, Lewis B, Young R, et al. Vital signs: changes in opioid prescribing in the United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017;66(26):697–704.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    U.S. Prescribing Rate Maps: Centers for Disease Control and Prevention. Available from: https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html. Accessed on 24 June 2018
  22. 22.
    Overdose Death Rates: National Institute on Drug Abuse. Available from: https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates. Accessed 24 June 2018
  23. 23.
    Fischer B, Vojtila L, Rehm J. The ‘fentanyl epidemic’ in Canada—some cautionary observations focusing on opioid-related mortality. Prev Med. 2018;107:109–13.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    National report: Apparent opioid-related deaths in Canada (released June 2018): Public Health Agency of Canada; 2018. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/national-report-apparent-opioid-related-deaths-released-june-2018.html. Accessed 20 June 2018.
  25. 25.
    Canadian Institute for Health Information. Pan-Canadian trends in the prescribing of opioids, 2012 to 2016. Ottawa: CIHI; 2017.Google Scholar
  26. 26.
    International Narcotics Control Board. Narcotic drugs: estimated world requirements for 2018; statistics for 2016. New York: United Nations; 2017.Google Scholar
  27. 27.
    Fischer B, Jones W, Krahn M, Rehm J. Differences and over-time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005-2010. Pharmacoepidemiol Drug Saf. 2011;20(12):1269–77.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Gomes T, Mamdani MM, Paterson JM, Dhalla IA, Juurlink DN. Trends in high-dose opioid prescribing in Canada. Can Fam Physician. 2014;60(9):826–32.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Fischer B, Jones W, Rehm J. Trends and changes in prescription opioid analgesic dispensing in Canada 2005-2012: an update with a focus on recent interventions. BMC Health Serv Res. 2014;14:90.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Health Canada. Canadian tobacco, alcohol and drugs survey (CTADS): 2015 summary2017 March 14, 2018. Available from: https://www.canada.ca/en/health-canada/services/canadian-tobacco-alcohol-drugs-survey/2015-summary.html.
  31. 31.
    Luce J, Strike C. A cross-Canada scan of methadone maintenance treatment policy developments. A report prepared for the Canadian executive council on addictions. 2011.Google Scholar
  32. 32.
    • Eibl JK, Morin K, Leinonen E, Marsh DC. The state of opioid agonist therapy in Canada 20 years after Federal Oversight. Can J Psychiatr. 2017;62(7):444–50. This paper provides an update of the state of opioid agonist treatment programs across Canada in 2017.CrossRefGoogle Scholar
  33. 33.
    U.S. Department of Health and Human Services. About the U.S. Opioid Epidemic: U.S. Department of Health and Human Services. 2018. Available from: https://www.hhs.gov/opioids/about-the-epidemic/. Accessed 8 March 2018
  34. 34.
    Baldwin N, Gray R, Goel A, Wood E, Buxton JA, Rieb LM. Fentanyl and heroin contained in seized illicit drugs and overdose-related deaths in British Columbia, Canada: an observational analysis. Drug Alcohol Depend. 2018;185:322–7.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Ho J, DeBeck K, Milloy MJ, Dong H, Wood E, Kerr T, et al. Increasing availability of illicit and prescription opioids among people who inject drugs in a Canadian setting, 2010-2014. Am J Drug Alcohol Abuse. 2018;44(3):368–77.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatr. 2014;71(7):821–6.CrossRefGoogle Scholar
  37. 37.
    Henry J Kaiser Family Foundation:Opioid overdose death rates and all drug overdose death rates per 100,000 population (age-adjusted). Available from: https://www.kff.org/other/state-indicator/opioid-overdose-death-rates/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Opioid%20Overdose%20Death%20Rate%20(Age-Adjusted)%22,%22sort%22:%22desc%22%7D. Accessed 26 June 2018
  38. 38.
    Gladstone EJ, Smolina K, Weymann D, Rutherford K, Morgan SG. Geographic variations in prescription opioid dispensations and deaths among women and men in British Columbia, Canada. Med Care. 2015;53(11):954–9.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Fischer B, Jones W, Rehm J. High correlations between levels of consumption and mortality related to strong prescription opioid analgesics in British Columbia and Ontario, 2005-2009. Pharmacoepidemiol Drug Saf. 2013;22(4):438–42.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    • O'Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM. Deaths involving fentanyl, fentanyl analogs, and U-47700 - 10 states, July-December 2016. MMWR Morb Mortal Wkly Rep. 2017;66(43):1197–202. This study highlights the rising contribution of fentanyl and fentanyl analogs to the drug overdose death rate in the United States.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    • Hayashi K, Milloy MJ, Lysyshyn M, DeBeck K, Nosova E, Wood E, et al. Substance use patterns associated with recent exposure to fentanyl among people who inject drugs in Vancouver, Canada: a cross-sectional urine toxicology screening study. Drug Alcohol Depend. 2018;183:1–6. This study documented high prevalence of exposure to fentanyl among people who inject drugs, with the majority of participants being unaware of this exposure. PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Amlani A, McKee G, Khamis N, Raghukumar G, Tsang E, Buxton JA. Why the FUSS (Fentanyl Urine Screen Study)? A cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia, Canada. Harm Reduct J. 2015;12:54.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Carroll JJ, Marshall BDL, Rich JD, Green TC. Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: a mixed methods study. Int J Drug Policy. 2017;46:136–45.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Macmadu A, Carroll JJ, Hadland SE, Green TC, Marshall BD. Prevalence and correlates of fentanyl-contaminated heroin exposure among young adults who use prescription opioids non-medically. Addict Behav. 2017;68:35–8.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Fleischauer AT, Ruhl L, Rhea S, Barnes E. Hospitalizations for endocarditis and associated health care costs among persons with diagnosed drug dependence - North Carolina, 2010-2015. MMWR Morb Mortal Wkly Rep. 2017;66(22):569–73.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Banerjee G, Edelman EJ, Barry DT, Becker WC, Cerda M, Crystal S, et al. Non-medical use of prescription opioids is associated with heroin initiation among US veterans: a prospective cohort study. Addiction. 2016;111(11):2021–31.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Liebling EJ, Green TC, Hadland SE, Marshall BDL. Injection drug use and overdose among young adults who use prescription opioids non-medically. Addict Behav. 2018;76:20–6.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Zibbell JE, Asher AK, Patel RC, Kupronis B, Iqbal K, Ward JW, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108(2):175–81.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Wejnert C, Hess KL, Hall HI, Van Handel M, Hayes D, Fulton P Jr, et al. Vital signs: trends in HIV diagnoses, risk behaviors, and prevention among persons who inject drugs - United States. MMWR Morb Mortal Wkly Rep. 2016;65(47):1336–42.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Burnett JC, Broz D, Spiller MW, Wejnert C, Paz-Bailey G. HIV infection and HIV-associated behaviors among persons who inject drugs - 20 cities, United States, 2015. MMWR Morb Mortal Wkly Rep. 2018;67(1):23–8.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Peters PJ, Pontones P, Hoover KW, Patel MR, Galang RR, Shields J, et al. HIV infection linked to injection use of oxymorphone in Indiana, 2014–2015. N Engl J Med. 2016;375(3):229–39.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Evans ME, Labuda SM, Hogan V, Agnew-Brune C, Armstrong J, Periasamy Karuppiah AB, et al. Notes from the field: HIV infection investigation in a rural area - West Virginia, 2017. MMWR Morb Mortal Wkly Rep. 2018;67(8):257–8.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Ronan MV, Herzig SJ. Hospitalizations related to opioid abuse/dependence and associated serious infections increased sharply, 2002-12. Health Aff (Millwood). 2016;35(5):832–7.CrossRefGoogle Scholar
  54. 54.
    Canadian Institute for Health Information. Opioid-related harms in Canada. Ottawa: CIHI; 2017.Google Scholar
  55. 55.
    Collins FS, Koroshetz WJ, Volkow ND. Helping to end addiction over the long-term: the research plan for the nih heal initiative. JAMA. 2018;320:129–30.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Alford DP, Zisblatt L, Ng P, Hayes SM, Peloquin S, Hardesty I, et al. SCOPE of pain: an evaluation of an opioid risk evaluation and mitigation strategy continuing education program. Pain Med. 2016;17(1):52–63.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Becker WC, Fiellin DA. Federal plan for prescriber education on opioids misses opportunities. Ann Intern Med. 2012;157(3):205–6.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    U.S. Department of Health and Human Services. Opioid abuse in the U.S. and the HHS actions to address opioid-drug related overdoses and death 2015. Available from: https://aspe.hhs.gov/basic-report/opioid-abuse-us-and-hhs-actions-address-opioid-drug-related-overdoses-and-deaths. Accessed 18 April 1018
  59. 59.
    Comprehensive Addiction and Recovery Act of 2016. Available from: https://www.govtrack.us/congress/bills/114/s524/text. Accessed on une 23 2018
  60. 60.
    Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain - United States, 2016. MMWR Recomm Rep. 2016;65(1):1–49.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    •• Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health. Reports of the Surgeon General. Washington (DC); 2016. This comprehensive report summarizes the chronic disease model of addiction and reviews evidence based approaches to addiction mangement.Google Scholar
  62. 62.
    Fischer B, Rehm J, Tyndall M. Effective Canadian policy to reduce harms from prescription opioids: learning from past failures. CMAJ. 2016;188(17–18):1240–4.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Gomes T, Mastorakos A, Paterson JM, Sketris I, Caetano P, Greaves S, et al. Changes in the dispensing of opioid medications in Canada following the introduction of a tamper-deterrent formulation of long-acting oxycodone: a time series analysis. CMAJ Open. 2017;5(4):E800–E7.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Fischer B, Rehm J, Patra J, Cruz MF. Changes in illicit opioid use across Canada. CMAJ. 2006;175(11):1385.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Socias ME, Ahamad K. An urgent call to increase access to evidence-based opioid agonist therapy for prescription opioid use disorders. CMAJ. 2016;188(17–18):1208–9.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Health Canada. Government of Canada: actions on Opiods, 2016 and 2017. Ottawa: Health Canada; 2017.Google Scholar
  67. 67.
    •• Bruneau J, Ahamad K, Goyer ME, Poulin G, Selby P, Fischer B, et al. Management of opioid use disorders: a national clinical practice guideline. CMAJ. 2018;190(9):E247–E57 This is the first-ever Canadian evidence-based guideline for the management of opioid use disorder. The guideline supports a stepped and integrated care approach, where treatment intensity is continually adjusted to match individual patient needs over time. PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Rutkow L, Vernick JS. Emergency legal authority and the opioid crisis. N Engl J Med. 2017;377(26):2512–4.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Haffajee RL, Jena AB, Weiner SG. Mandatory use of prescription drug monitoring programs. JAMA. 2015;313(9):891–2.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    •• Fink DS, Schleimer JP, Sarvet A, Grover KK, Delcher C, Castillo-Carniglia A, et al. Association between prescription drug monitoring programs and nonfatal and fatal drug overdoses: a systematic review. Ann Intern Med. 2018;168(11):783–90. This is one of the first studies to systematically evaluate the literature regarding the relationship between prescription drug monitoring programs and overdose rates in the United States. PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Soelberg CD, Brown RE Jr, Du Vivier D, Meyer JE, Ramachandran BK. The US opioid crisis: current federal and state legal issues. Anesth Analg. 2017;125(5):1675–81.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Davis C, Carr D. State legal innovations to encourage naloxone dispensing. J Am Pharm Assoc (2003). 2017;57(2S):S180–S4.CrossRefGoogle Scholar
  73. 73.
    Des Jarlais DC. Harm reduction in the USA: the research perspective and an archive to David purchase. Harm Reduct J. 2017;14(1):51.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Bouvier BA, Elston B, Hadland SE, Green TC, Marshall BD. Willingness to use a supervised injection facility among young adults who use prescription opioids non-medically: a cross-sectional study. Harm Reduct J. 2017;14(1):13.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Kral AH, Wenger L, Carpenter L, Wood E, Kerr T, Bourgois P. Acceptability of a safer injection facility among injection drug users in San Francisco. Drug Alcohol Depend. 2010;110(1–2):160–3.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Lysyshyn M, Dohoo C, Forsting S, Kerr T, McNeil R. Evaluation of a fentanyl drug checking program for clients of a supervised injection site, Vancouver, Canada. Montreal: Harm Reduction International; 2017.Google Scholar
  77. 77.
    Guidance for Injectable Opioid Agonist Treatment for Opioid Use Disorder. Vancouve: BC Centre on Substance Use; 2017 [cited 2018 March 21]. Available from: http://www.bccsu.ca/wp-content/uploads/2017/10/BC-iOAT-Guidelines-10.2017.pdf.
  78. 78.
    B.C. nurse practitioners can now prescribe drugs for opioid addiction. Vancouver Sun. 2018 (col. 2018).Google Scholar
  79. 79.
    Tyndall M. An emergency response to the opioid overdose crisis in Canada: a regulated opioid distribution program. CMAJ. 2018;190(2):E35–E6.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    D'Onofrio G, Chawarski MC, O'Connor PG, Pantalon MV, Busch SH, Owens PH, et al. Emergency department-initiated buprenorphine for opioid dependence with continuation in primary care: outcomes during and after intervention. J Gen Intern Med. 2017;32(6):660–6.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    D'Onofrio G, O'Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636–44.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Hering R, Lefebvre L, Stewart P, Selby P. Increasing addiction medicine capacity in Canada: the case for collaboration in education and research. Can J Addict. 2014;5(3):10–4.Google Scholar
  83. 83.
    Holt SR, Segar N, Cavallo DA, Tetrault JM. The addiction recovery clinic: a novel, primary-care-based approach to teaching addiction medicine. Acad Med. 2017;92(5):680–3.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Joseph H. Donroe
    • 1
    Email author
  • M. Eugenia Socias
    • 2
    • 3
  • Brandon D. L. Marshall
    • 4
  1. 1.Department of Internal MedicineYale University School of MedicineNew HavenUSA
  2. 2.British Columbia Centre on Substance UseVancouverCanada
  3. 3.Department of MedicineUniversity of British ColumbiaVancouverCanada
  4. 4.Department of EpidemiologyBrown University School of Public HealthProvidenceUSA

Personalised recommendations